Implication of 5-HT2 receptor subtypes in the mechanism of action of antidepressants in the four plates test

Abstract

These results indicate that the co-administration of 5-HT2 receptor agonists with paroxetine and venlafaxine may provide a powerful tool for enhancing the clinical efficacy of these antidepressants.

Structure–Activity Relationships of Phenylalkylamines as Agonist Ligands for 5‐HT2A Receptors

“…Moreover, subtype and functionally selective ligands may hold valuable therapeutic potential. Functionally selective, signal pathway specific ligands that are nonhallucinogenic in nature, might eventually be used to augment pharmacological psychiatric therapies for depression [36] and anxiety. [38,39] In cognitive pharmacology, these agents might prove useful in memory, [25] learning, [26] and BDNF-mediated processes.…”

“…[33,34] Both 5-HT 2A and 5-HT 2B receptors were found to mediate liver regeneration in a partial hepatectomy model. [35] Drugs that target 5-HT 2 receptors are used in the treatment of various psychiatric disorders, including depression, [36] anxiety, [37][38][39] obsessive-compulsive disorders, [40] and schizophrenia. [41,42] Many antipsychotic drugs are 5-HT 2A receptor inverse agonists or antagonists.…”

“…[17,57,58] Agonist activation of 5-HT 2 receptors has been the subject of recent studies, indicating a growing interest in the therapeutic potential underlying activation of this class of receptors. [18,32,35,36,38,40,50] 5-HT 2 receptor agonists generally show little subtype selectivity, however, some selective agonists have been designed for 5-HT 2B and 5-HT 2C receptors. [32,59,60] The identification of agonists with 5-HT 2A receptor subtype selectivity lags behind, and the need for their development has been acknowledged.…”

Differential Effects of Ziprasidone and Haloperidol on Immobilization-Stress-Induced CRF mRNA Expression in the Hypothalamic Paraventricular Nucleus of Rats

“…In addition, ziprasione has activities on 5-HT 1A and 5-HT 2A receptors. So, ziprasidone may be related to antidepressant mechanism [18] . According to Barbee et al [19] , 10% of the treatment-resistant depressive patients responded to ziprasidone therapy.…”

The role of serotonin-2 (5-HT2) and dopamine receptors in the behavioral actions of the 5-HT2A/2C agonist, DOI, and putative 5-HT2C inverse agonist, SR46349B

“…The doses of SB242084 and raclopride were chosen since they were shown to inhibit 5HT 2 agonistelicited behaviors in rodents (Yonezawa et al 2008;Stiedl et al 2007;Schreiber et al 1995). SR46349B doses were based on the initial studies by Rinaldi-Carmona et al (1992) and behavioral studies which showed an effect at the 0.1-mg/kg dose in mice (Nic Dhonnchadha et al 2005;Ripoll et al 2006).…”